




2017 National Preferred Formulary Update




Smart formulary management

Through the National Preferred Formulary



Ongoing formulary management



National Preferred Formulary — FY 2015 Savings to State of Delaware

\$5,268,122

in FY2015 savings
tied to formulary
exclusions

74

TOTAL EXCLUSIONS

5.1%

MEMBER IMPACT

8.1%

MEMBERS PURSUED A
CLINICAL EXCEPTION

National Preferred Formulary – FY 2016 Savings to State of Delaware

\$6,337,889

in FY2016 savings
tied to formulary
exclusions

87

TOTAL EXCLUSIONS

4.1%

MEMBER IMPACT

10.7%

**MEMBERS PURSUED A
CLINICAL EXCEPTION**

Building on our momentum: 2017 formulary updates



State of Delaware impact

0.06%	New exclusions (33 patients)
-------	------------------------------

0.02%	Preferred to non-preferred (13 patients)
-------	--

0.08% Total

85 Total Exclusions

Drug detail for newly excluded drugs



New 2017 NPF exclusions

	Medications	
Therapy classes	Exclusions/ Member Impacts	Alternatives
Dermatological Topical actinic keratosis	Zyclara/9 members	diclofenac sodium, fluorouracil, imiquimod 5% cream, Carac, Picato
Inflammatory conditions Tumor necrosis factor antagonists and other drugs for inflammatory conditions	Orencia/10 members Kineret/0 members	Actemra, Enbrel, Humira, Remicade, Xeljanz, Xeljanz XR
	Taltz/0 members	Enbrel, Cosentyx, Humira, Otezla, Stelara
Gout therapy* Colchicine products	Colchicine – AB/14 members	Colcrys, Mitigare

* New exclusion class for 2017

2017 Preferred to Nonpreferred Changes


	Medications	
Therapy classes	NonPreferred/ Member Impacts	Preferred Alternatives
Dermatological Acne	Differin/4 members	adapalene
Asthma	Foradil/1 member	Striverdi
Seizures	Oxtellar XR/4 members	oxcarbazepine
Diabetes	Riomet/4 members	metformin

2017 exclusion list removals

Therapy class	2016 excluded drugs	2017 status
Antiotensin II receptor antagonists + diuretic combinations	Edarbi/Edarbyclor Teveten HCT	Nonpreferred
Tumor necrosis factor antagonists and other drugs for inflammatory conditions	Xeljanz/Xeljanz XR	Preferred
Pulmonary anti-inflammatory inhalers	Arnuity Ellipta Flovent Diskus/HFA	Preferred

Additionally 11 drugs will move from non-preferred to preferred status on 1/1/17 for a positive impact for 23 patients for State of Delaware


Communications plan



Comprehensive, proven communication plan

Tailored and timely

2017 Formulary Changes Communication Plan



Members

- Communications to targeted plan members

Providers

- Communications to prescribers and pharmacists

Sample Materials

- Available upon request